Timely surveillance of respiratory syncytial virus (RSV) cases in children showed recent increased circulation

In a preprint, not yet peer-reviewed, CITF-funded researcher Dr. Pascal Lavoie (University of British Columbia) and colleagues found that children in British Columbia have been more vulnerable to respiratory syncytial virus (RSV) following a lull while protective measures were in place at the height of the COVID-19 pandemic.

2022-11-28T16:45:07-05:00November 28, 2022|Pediatrics|

Risk factors for SARS-CoV-2 seropositivity and seroconversion among children and adolescents in Montreal

In a preprint, not yet peer-reviewed, CITF-funded researchers Drs. Kate Zinszer (University of Montreal) and Caroline Quach (University of Montreal, Research Centre of the Sainte-Justine University Hospital) identified a variety of factors that contributed to an increased risk of seropositivity and seroconversion in children and adolescents.

2022-11-08T09:32:19-05:00November 7, 2022|Pediatrics|

The methodology of the CHILD sub-study to examine the effect of SARS-CoV-2 infection on children

In a pre-print, not yet peer reviewed, Dr. Meghan Azad (University of Manitoba) and her team reported on the study design and cohort profile for research examining the prevalence and predictors of SARS-CoV-2 infection and transmission, as well as the predictors of the health and psychosocial impacts from the COVID-19 pandemic among Canadian children and their families.

2022-10-31T15:02:33-04:00October 31, 2022|Pediatrics|

How adolescents with inflammatory bowel disease treated with immunosuppressive drugs respond to COVID-19 vaccination

In a letter published in Gut, Dr. Kevan Jacobson, Dr. Pascal Lavoie and collaborators from the University of British Columbia report modestly lower antibody levels in adolescents, aged 12 to 17 years, with inflammatory bowel disease (IBD) who are on the anti-TNF-a anti-inflammatory therapy infliximab in combination with other immunosuppressive drugs or given as monotherapy, after a first dose of Pfizer-BioNTech’s Comirnaty vaccine.

2022-04-22T15:41:26-04:00November 30, 2021|Pediatrics|
Go to Top